

Cardiomyopathy Medication Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/CDE5E8C5943CEN.html>

Date: March 2022

Pages: 62

Price: US\$ 3,250.00 (Single User License)

ID: CDE5E8C5943CEN

Abstracts

Cardiomyopathy is a group of diseases that affect the heart muscle. Early on there may be few or no symptoms. As the disease worsens, shortness of breath, feeling tired, and swelling of the legs may occur, due to the onset of heart failure. An irregular heart beat and fainting may occur. Those affected are at an increased risk of sudden cardiac death.

This report contains market size and forecasts of Cardiomyopathy Medication in Global, including the following market information:

Global Cardiomyopathy Medication Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Cardiomyopathy Medication market was valued at 440.5 million in 2021 and is projected to reach US\$ 523.1 million by 2028, at a CAGR of 2.5% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Anticoagulants Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cardiomyopathy Medication include Pfizer, Roche, Sanofi, AstraZeneca, Merck, Teva Pharmaceutical, Johnson & Johnson, PhaseBio Pharmaceuticals and Capricor Therapeutics and etc. In 2021, the global top five players

have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cardiomyopathy Medication companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cardiomyopathy Medication Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Cardiomyopathy Medication Market Segment Percentages, by Type, 2021 (%)

Anticoagulants

Antiarrhythmics

Anti-Hypertensives

Cardiac Glycosides

Others

Global Cardiomyopathy Medication Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Cardiomyopathy Medication Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Homecare

Others

Global Cardiomyopathy Medication Market, By Region and Country, 2017-2022,
2023-2028 (\$ Millions)

Global Cardiomyopathy Medication Market Segment Percentages, By Region and
Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cardiomyopathy Medication revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Cardiomyopathy Medication revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Roche

Sanofi

AstraZeneca

Merck

Teva Pharmaceutical

Johnson & Johnson

PhaseBio Pharmaceuticals

Capricor Therapeutics

MyoKardia

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Cardiomyopathy Medication Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Cardiomyopathy Medication Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL CARDIOMYOPATHY MEDICATION OVERALL MARKET SIZE

- 2.1 Global Cardiomyopathy Medication Market Size: 2021 VS 2028
- 2.2 Global Cardiomyopathy Medication Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Cardiomyopathy Medication Players in Global Market
- 3.2 Top Global Cardiomyopathy Medication Companies Ranked by Revenue
- 3.3 Global Cardiomyopathy Medication Revenue by Companies
- 3.4 Top 3 and Top 5 Cardiomyopathy Medication Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Cardiomyopathy Medication Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Cardiomyopathy Medication Players in Global Market
 - 3.6.1 List of Global Tier 1 Cardiomyopathy Medication Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Cardiomyopathy Medication Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Cardiomyopathy Medication Market Size Markets, 2021 & 2028

4.1.2 Anticoagulants

4.1.3 Antiarrhythmics

4.1.4 Anti-Hypertensives

4.1.5 Cardiac Glycosides

4.1.6 Others

4.2 By Type - Global Cardiomyopathy Medication Revenue & Forecasts

4.2.1 By Type - Global Cardiomyopathy Medication Revenue, 2017-2022

4.2.2 By Type - Global Cardiomyopathy Medication Revenue, 2023-2028

4.2.3 By Type - Global Cardiomyopathy Medication Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Cardiomyopathy Medication Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Homecare

5.1.5 Others

5.2 By Application - Global Cardiomyopathy Medication Revenue & Forecasts

5.2.1 By Application - Global Cardiomyopathy Medication Revenue, 2017-2022

5.2.2 By Application - Global Cardiomyopathy Medication Revenue, 2023-2028

5.2.3 By Application - Global Cardiomyopathy Medication Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Cardiomyopathy Medication Market Size, 2021 & 2028

6.2 By Region - Global Cardiomyopathy Medication Revenue & Forecasts

6.2.1 By Region - Global Cardiomyopathy Medication Revenue, 2017-2022

6.2.2 By Region - Global Cardiomyopathy Medication Revenue, 2023-2028

6.2.3 By Region - Global Cardiomyopathy Medication Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Cardiomyopathy Medication Revenue, 2017-2028

6.3.2 US Cardiomyopathy Medication Market Size, 2017-2028

6.3.3 Canada Cardiomyopathy Medication Market Size, 2017-2028

6.3.4 Mexico Cardiomyopathy Medication Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Cardiomyopathy Medication Revenue, 2017-2028

6.4.2 Germany Cardiomyopathy Medication Market Size, 2017-2028

6.4.3 France Cardiomyopathy Medication Market Size, 2017-2028

6.4.4 U.K. Cardiomyopathy Medication Market Size, 2017-2028

6.4.5 Italy Cardiomyopathy Medication Market Size, 2017-2028

6.4.6 Russia Cardiomyopathy Medication Market Size, 2017-2028

6.4.7 Nordic Countries Cardiomyopathy Medication Market Size, 2017-2028

6.4.8 Benelux Cardiomyopathy Medication Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Cardiomyopathy Medication Revenue, 2017-2028

6.5.2 China Cardiomyopathy Medication Market Size, 2017-2028

6.5.3 Japan Cardiomyopathy Medication Market Size, 2017-2028

6.5.4 South Korea Cardiomyopathy Medication Market Size, 2017-2028

6.5.5 Southeast Asia Cardiomyopathy Medication Market Size, 2017-2028

6.5.6 India Cardiomyopathy Medication Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Cardiomyopathy Medication Revenue, 2017-2028

6.6.2 Brazil Cardiomyopathy Medication Market Size, 2017-2028

6.6.3 Argentina Cardiomyopathy Medication Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Cardiomyopathy Medication Revenue, 2017-2028

6.7.2 Turkey Cardiomyopathy Medication Market Size, 2017-2028

6.7.3 Israel Cardiomyopathy Medication Market Size, 2017-2028

6.7.4 Saudi Arabia Cardiomyopathy Medication Market Size, 2017-2028

6.7.5 UAE Cardiomyopathy Medication Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer

7.1.1 Pfizer Corporate Summary

7.1.2 Pfizer Business Overview

7.1.3 Pfizer Cardiomyopathy Medication Major Product Offerings

7.1.4 Pfizer Cardiomyopathy Medication Revenue in Global Market (2017-2022)

7.1.5 Pfizer Key News

7.2 Roche

7.2.1 Roche Corporate Summary

- 7.2.2 Roche Business Overview
- 7.2.3 Roche Cardiomyopathy Medication Major Product Offerings
- 7.2.4 Roche Cardiomyopathy Medication Revenue in Global Market (2017-2022)
- 7.2.5 Roche Key News
- 7.3 Sanofi
 - 7.3.1 Sanofi Corporate Summary
 - 7.3.2 Sanofi Business Overview
 - 7.3.3 Sanofi Cardiomyopathy Medication Major Product Offerings
 - 7.3.4 Sanofi Cardiomyopathy Medication Revenue in Global Market (2017-2022)
 - 7.3.5 Sanofi Key News
- 7.4 AstraZeneca
 - 7.4.1 AstraZeneca Corporate Summary
 - 7.4.2 AstraZeneca Business Overview
 - 7.4.3 AstraZeneca Cardiomyopathy Medication Major Product Offerings
 - 7.4.4 AstraZeneca Cardiomyopathy Medication Revenue in Global Market (2017-2022)
 - 7.4.5 AstraZeneca Key News
- 7.5 Merck
 - 7.5.1 Merck Corporate Summary
 - 7.5.2 Merck Business Overview
 - 7.5.3 Merck Cardiomyopathy Medication Major Product Offerings
 - 7.5.4 Merck Cardiomyopathy Medication Revenue in Global Market (2017-2022)
 - 7.5.5 Merck Key News
- 7.6 Teva Pharmaceutical
 - 7.6.1 Teva Pharmaceutical Corporate Summary
 - 7.6.2 Teva Pharmaceutical Business Overview
 - 7.6.3 Teva Pharmaceutical Cardiomyopathy Medication Major Product Offerings
 - 7.6.4 Teva Pharmaceutical Cardiomyopathy Medication Revenue in Global Market (2017-2022)
 - 7.6.5 Teva Pharmaceutical Key News
- 7.7 Johnson & Johnson
 - 7.7.1 Johnson & Johnson Corporate Summary
 - 7.7.2 Johnson & Johnson Business Overview
 - 7.7.3 Johnson & Johnson Cardiomyopathy Medication Major Product Offerings
 - 7.7.4 Johnson & Johnson Cardiomyopathy Medication Revenue in Global Market (2017-2022)
 - 7.7.5 Johnson & Johnson Key News
- 7.8 PhaseBio Pharmaceuticals
 - 7.8.1 PhaseBio Pharmaceuticals Corporate Summary
 - 7.8.2 PhaseBio Pharmaceuticals Business Overview

- 7.8.3 PhaseBio Pharmaceuticals Cardiomyopathy Medication Major Product Offerings
- 7.8.4 PhaseBio Pharmaceuticals Cardiomyopathy Medication Revenue in Global Market (2017-2022)
- 7.8.5 PhaseBio Pharmaceuticals Key News
- 7.9 Capricor Therapeutics
 - 7.9.1 Capricor Therapeutics Corporate Summary
 - 7.9.2 Capricor Therapeutics Business Overview
 - 7.9.3 Capricor Therapeutics Cardiomyopathy Medication Major Product Offerings
 - 7.9.4 Capricor Therapeutics Cardiomyopathy Medication Revenue in Global Market (2017-2022)
 - 7.9.5 Capricor Therapeutics Key News
- 7.10 MyoKardia
 - 7.10.1 MyoKardia Corporate Summary
 - 7.10.2 MyoKardia Business Overview
 - 7.10.3 MyoKardia Cardiomyopathy Medication Major Product Offerings
 - 7.10.4 MyoKardia Cardiomyopathy Medication Revenue in Global Market (2017-2022)
 - 7.10.5 MyoKardia Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Cardiomyopathy Medication Market Opportunities & Trends in Global Market

Table 2. Cardiomyopathy Medication Market Drivers in Global Market

Table 3. Cardiomyopathy Medication Market Restraints in Global Market

Table 4. Key Players of Cardiomyopathy Medication in Global Market

Table 5. Top Cardiomyopathy Medication Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Cardiomyopathy Medication Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Cardiomyopathy Medication Revenue Share by Companies, 2017-2022

Table 8. Global Companies Cardiomyopathy Medication Product Type

Table 9. List of Global Tier 1 Cardiomyopathy Medication Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Cardiomyopathy Medication Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Cardiomyopathy Medication Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Cardiomyopathy Medication Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Cardiomyopathy Medication Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Cardiomyopathy Medication Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Cardiomyopathy Medication Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Cardiomyopathy Medication Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Cardiomyopathy Medication Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Cardiomyopathy Medication Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Cardiomyopathy Medication Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Cardiomyopathy Medication Revenue, (US\$,

Mn), 2023-2028

Table 22. By Country - Europe Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Cardiomyopathy Medication Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Cardiomyopathy Medication Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Cardiomyopathy Medication Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Cardiomyopathy Medication Revenue, (US\$, Mn), 2023-2028

Table 30. Pfizer Corporate Summary

Table 31. Pfizer Cardiomyopathy Medication Product Offerings

Table 32. Pfizer Cardiomyopathy Medication Revenue (US\$, Mn), (2017-2022)

Table 33. Roche Corporate Summary

Table 34. Roche Cardiomyopathy Medication Product Offerings

Table 35. Roche Cardiomyopathy Medication Revenue (US\$, Mn), (2017-2022)

Table 36. Sanofi Corporate Summary

Table 37. Sanofi Cardiomyopathy Medication Product Offerings

Table 38. Sanofi Cardiomyopathy Medication Revenue (US\$, Mn), (2017-2022)

Table 39. AstraZeneca Corporate Summary

Table 40. AstraZeneca Cardiomyopathy Medication Product Offerings

Table 41. AstraZeneca Cardiomyopathy Medication Revenue (US\$, Mn), (2017-2022)

Table 42. Merck Corporate Summary

Table 43. Merck Cardiomyopathy Medication Product Offerings

Table 44. Merck Cardiomyopathy Medication Revenue (US\$, Mn), (2017-2022)

Table 45. Teva Pharmaceutical Corporate Summary

Table 46. Teva Pharmaceutical Cardiomyopathy Medication Product Offerings

Table 47. Teva Pharmaceutical Cardiomyopathy Medication Revenue (US\$, Mn), (2017-2022)

Table 48. Johnson & Johnson Corporate Summary

Table 49. Johnson & Johnson Cardiomyopathy Medication Product Offerings

Table 50. Johnson & Johnson Cardiomyopathy Medication Revenue (US\$, Mn),

(2017-2022)

Table 51. PhaseBio Pharmaceuticals Corporate Summary

Table 52. PhaseBio Pharmaceuticals Cardiomyopathy Medication Product Offerings

Table 53. PhaseBio Pharmaceuticals Cardiomyopathy Medication Revenue (US\$, Mn),
(2017-2022)

Table 54. Capricor Therapeutics Corporate Summary

Table 55. Capricor Therapeutics Cardiomyopathy Medication Product Offerings

Table 56. Capricor Therapeutics Cardiomyopathy Medication Revenue (US\$, Mn),
(2017-2022)

Table 57. MyoKardia Corporate Summary

Table 58. MyoKardia Cardiomyopathy Medication Product Offerings

Table 59. MyoKardia Cardiomyopathy Medication Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Cardiomyopathy Medication Segment by Type in 2021
- Figure 2. Cardiomyopathy Medication Segment by Application in 2021
- Figure 3. Global Cardiomyopathy Medication Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Cardiomyopathy Medication Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Cardiomyopathy Medication Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Cardiomyopathy Medication Revenue in 2021
- Figure 8. By Type - Global Cardiomyopathy Medication Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Cardiomyopathy Medication Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Cardiomyopathy Medication Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Cardiomyopathy Medication Revenue Market Share, 2017-2028
- Figure 12. US Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Cardiomyopathy Medication Revenue Market Share, 2017-2028
- Figure 16. Germany Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Cardiomyopathy Medication Revenue Market Share, 2017-2028
- Figure 24. China Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028

Figure 28. India Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Cardiomyopathy Medication Revenue Market Share, 2017-2028

Figure 30. Brazil Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Cardiomyopathy Medication Revenue Market Share, 2017-2028

Figure 33. Turkey Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Cardiomyopathy Medication Revenue, (US\$, Mn), 2017-2028

Figure 37. Pfizer Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Roche Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Sanofi Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. AstraZeneca Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Merck Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Teva Pharmaceutical Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Johnson & Johnson Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. PhaseBio Pharmaceuticals Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Capricor Therapeutics Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. MyoKardia Cardiomyopathy Medication Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Cardiomyopathy Medication Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/CDE5E8C5943CEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDE5E8C5943CEN.html>